Guru Sonpavde, MD

Medical Director (Urology), Medical Oncologist

Clinical Cancer Research

Expertise of Guru Sonpavde, MD

Biography: Guru P. Sonpavde, MD serves as the Medical Director of Genitourinary (GU) Oncology and the Phase I Clinical Research Unit and Christopher K. Glanz Chair for Bladder Cancer Research () at the AdventHealth Cancer Institute (List of active Phase I trials here: Search for: In Celebration, FL, Recruiting studies, Phase: 1 | Card Results | ClinicalTrials.gov). Previously, he was Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School from 2017-2022, GU Oncology Director and Associate Professor of Medicine at the University of Alabama at Birmingham from 2012 to 2017 and practiced from 2004 to 2012 at Texas Oncology.

Dr. Sonpavde’s focus is drug development and translational research to cure GU cancers, which have led to approximately 500 publications (sonpavde - Search Results - PubMed). In addition to his expertise in Urologic Medical Oncology, he also conducts Phase I clinical trials. He is a member of Southwest Oncology Group, Scientific Advisory Board of the Bladder Cancer Advocacy Network (BCAN), and the Bladder Cancer Task Force of U.S. NCI GU Steering Committee. He was cited in TIME magazine regarding his participation in clinical trials in August 2022 (Clinical Trials for Bladder Cancer | TIME).”
Education: University of Madras
Residency: Internal Medicine at Nassau County Medical Center
Fellowship: Hematology & Oncology at Indiana University School of Medicine
Board Certifications: Medical Oncology: The American Board of Internal Medicine

Internal Medicine: The American Board of Internal Medicine

Publications

Vaccine approaches to treat urothelial cancer

2024, HUMAN VACCINES & IMMUNOTHERAPEUTICS
Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer

2024, CLINICAL GENITOURINARY CANCER
Evaluation of American Joint Committee on Cancer and alternative tumour classification systems for primary penile squamous cell carcinoma

2024, BRITISH JOURNAL OF DERMATOLOGY

More sources loaded
New Therapeutic Horizons for Advanced or Metastatic Penile Cancer

2024, UROLOGIC CLINICS OF NORTH AMERICA
Factors predictive of recurrence, metastasis and death in node-negative penile squamous cell carcinoma: A retrospective multicentre cohort study

2024, JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
The evolving treatment landscape of metastatic urothelial cancer

2024, NATURE REVIEWS UROLOGY
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes

2024, JOURNAL FOR IMMUNOTHERAPY OF CANCER
Unlocking precision oncology with FGFR inhibition in urothelial carcinoma

2024, ANNALS OF ONCOLOGY
Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer

2024, JOURNAL FOR IMMUNOTHERAPY OF CANCER
Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review

2024, EUROPEAN UROLOGY ONCOLOGY

Associated Clinical Trials for Guru Sonpavde, MD

NCT06457997

First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients with Advanced Solid Tumors

This study is currently enrolling.

Associated Conditions: Metastatic Solid Tumors

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

The Sponsor will use tumor tissue samples along with other health information collected during the main study to conduct exploratory research in order to learn about the following: Why some people...
rhPSMA-7.3(18F)-PET scan to detect prostate cancer in patients with early PSA recurrence.

This study is currently enrolling.

Associated Conditions: Prostate Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

The research is being done at the Radiology Nuclear Medicine Department of AdventHealth Orlando and Celebration. Patients are instructed to drink water prior to administration of flotufolastat F-18 to...
NCT05858164

An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase alpha inhibitor (DGKai) BAY 2862789 in participants with advanced solid tumors

This study is currently enrolling.

Associated Conditions: Metastatic Solid Tumors

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

This study is being done to learn more about a new drug called BAY 2862789, an inhibitor of diacylglycerol kinase alpha (DGKα). BAY 2862789 is an immunotherapy drug that has been developed to activate...

More clinical trials loaded
NCT05987241

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer A032103

This study is currently enrolling.

Associated Conditions: Bladder Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

This study is being done to answer the following question: After having your bladder surgically removed after being diagnosed with bladder cancer, can we better identify which patients need an...
NCT06307795

A Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.

This study is currently enrolling.

Associated Conditions: Metastatic Solid Tumors

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in...
NCT06318273

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer

This study is currently enrolling.

Research Area: Clinical Cancer Research

The purpose of this study is to see if the study drug is safe and tolerable.
This study will consist of 2 main phases: dose escalation (Part 1) and dose expansion (Part 2). In Part 1, multiple...
NCT06238479

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

This study is currently enrolling.

Associated Conditions: Multiple Myeloma

Research Area: Clinical Cancer Research

You are being invited to take part in this study because you have been diagnosed with a type of cancer that may express a protein called nectin-4, which LY4101174 is designed to treat and you have...
NCT05914116

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

This study is currently enrolling.

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

The main goal of this study is to test whether the study drug is safe and tolerable in patients with advanced/unresectable, or metastatic solid tumors (including small cell lung cancer, non-small cell...
NCT06305767

A Phase 2, Randomized, Double-blind Study of Adjuvant V940 (mRNA-4157) + Pembrolizumab (MK-3475) vs. Placebo + Pembrolizumab for High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) Post-Radical Resection

This study is currently enrolling.

Associated Conditions: Urothelial Cancer

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

To compare V940 plus pembrolizumab to
placebo plus pembrolizumab with respect to DFS. Hypothesis (H1): V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS as assessed...
NCT05592626

CP-START-001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

This study is currently enrolling.

Associated Conditions: Metastatic Solid Tumors

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

The purpose of this research study is
To test the safety of study drug STAR0602. To see how well different doses of the study drug STAR0602 are tolerated in different groups of patients. To understand...
NCT05948865

CPO301-US-101: A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors

This study is currently enrolling.

Associated Conditions: Multiple Myeloma

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

The purpose of the study, called CPO301-US-101, is to see if CPO301 (also known as SYS6010) is safe and effective in treating your type of cancer when administered as an intravenous (administered into...
NCT05639751

PRT3789-01: A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

This study is currently enrolling.

Associated Conditions: Lung Cancer

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

The purpose of this research study is to test the safety of PRT3789 at different dose levels to find out what effects, good and/or bad, PRT3789 has on you and your type of cancer. The information...
NCT04561362

BT8009-100: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies

This study is currently enrolling.

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida
NCT05614739

AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS

This study is currently enrolling.

Associated Conditions: Multiple Tumor Types

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS
NCT05929235

A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

This study is not currently enrolling.

Associated Conditions: Urothelial Cancer

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida
NCT05514717

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2

This study is not currently enrolling.

Associated Conditions: Metastatic Solid Tumors

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

The purpose of the study is to: During the Dose Escalation part, find the most tolerated dose of the Study Drug that may provide potential benefit. During the Enrichment and Expansion parts, further...
NCT06172478

A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

This study is not currently enrolling.

Research Area: Clinical Cancer Research

The purpose of this study is to learn more about an investigational drug called patritumab deruxtecan (also known as HER3-DXd or U3-1402), also referred to as “study drug” or “study treatment”...
NCT05891171

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors

This study is not currently enrolling.

Research Area: Clinical Cancer Research

Objectives: Primary: Dose Escalation: To identify the recommended doses for expansion (RDEs) of NKT3447 in adult subjects with advanced/metastatic solid tumors Dose Expansion: To evaluate the...
NCT06253130

EIK1003-001 (IMP1734-101): A first-in-human, Phase 1/2, open-label, multi-center, dose escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors

This study is not currently enrolling.

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

The study treatment is IMP1734, which is an experimental drug which means that regulatory authorities have allowed the study to be tested in this clinical trial for its potential to treat cancers in...
NCT06026410

KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors

This study is not currently enrolling.

Associated Conditions: Multiple Tumor Types

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

The purposes of this study are to:
• Determine the highest tolerable dose of KO-2806 given orally (by mouth) in combination with cabozantinib.
• Determine whether KO-2806 has an antitumor effect...
NCT05176483

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)

This study is not currently enrolling.

Associated Conditions: Multiple Tumor Types

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

You are being asked to take part in a clinical research study called STELLAR-002 because you have been diagnosed with cancer or your cancer has worsened since your last treatment. If you join this...
NCT05194072

A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors

This study is not currently enrolling.

Associated Conditions: Multiple Tumor Types

Research Area: Clinical Cancer Research
NCT04140526

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.

This study is not currently enrolling.

Associated Conditions: Multiple Tumor Types

Research Area: Clinical Cancer Research

Research Location: Celebration, Florida

This is a research study to find out if an experimental drug called ONC-392 is safe and effective in cancer patients and how the drug is absorbed and processed in the body of patients with cancer. ONC...
NCT04669899

Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

This study is not currently enrolling.

Associated Conditions: Multiple Myeloma

Research Area: Clinical Cancer Research

A medical research study for participants who have been diagnosed with a solid tumor (i.e. cancer) and currently, the tumor is unresponsive to approved treatments, approved treatments are worsening...